Journal of Medicinal Chemistry · 2023 · 12 citations · 17 references
Life SciencesMedicinal ChemistryOncologyBiophotonicsCancer PharmacologyMolecular OncologyPhotocatalysisProtein DegradationProtein DimerizationProtein OxidationProtein-ligand InteractionsAnticancer ActivityPhotocatalytic OxidationPhotolytic DegradationPhotooxidationPhotooxidative DamagePhotosensitizersPhotosensitizing CompoundsResistance To Targeted Therapy
In this work, we described a photocatalytic approach, termed ligand-directed photodegradation of interacting proteins (LDPIP), for efficient protein–protein heterodimer degradation. This LDPIP approach utilizes a combination of a photosensitizing protein ligand and appropriate light and molecular oxygen to induce oxidative damage to the ligand-binding protein as well as its interacting protein partner. As a showcase study, a photosensitizing HER2 ligand HER-PS-I was rationally designed based on the FDA-approved HER2 inhibitor lapatinib to efficiently degrade HER2 together with its interacting protein partner HER3, which is thought to induce HER2-targeted therapy resistance and difficult to target by small molecules. HER-PS-I exhibited excellent anticancer activity against drug-resistant MDA-MB-453 cells and its three-dimensional multicellular spheroids. We hope that this LDPIP approach would find more applications in degrading proteins that are thought undruggable or difficult to drug.
17
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gϋnter von Minckwitz, Marion Procter, Evandro de Azambuja et al. · New England Journal of Medicine · 2017 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia Sergina, Megan Rausch, Donghui Wang et al. · Nature · 2007 · 989 citations · Full text
Medicine, Cancer Biology, Oncology +14
Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations
Medicine, Oncology, Pharmacology +14